The well-known immunomodulatory drug antithymocyte globulin (ATG) can effectively inhibit the progression of type 1 diabetes (T1D) in young patients at low doses, while at the same time having a favorable safety profile. This is indicated by new results from the MELD-ATG study, which were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
